AstraZeneca announced top-line results from Terranova, the second of two pivotal Phase III trials for Fasenra in patients with moderate to very severe chronic obstructive pulmonary disease. The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations. This news follows the announcement earlier this month that the first pivotal Phase III trial, Galathea, did not meet its primary endpoint, AstraZeneca pointed out. “The safety and tolerability findings in Terranova were consistent with those observed in previous trials with Fasenra. A full evaluation of the data is ongoing, and the results will be submitted for presentation at a forthcoming medical meeting. The Company does not currently intend to make a regulatory submission,” it added.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.